Cargando…

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodenburg, RJ, Eskens, FALM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526773/ https://www.ncbi.nlm.nih.gov/pubmed/31190952 http://dx.doi.org/10.2147/IJNRD.S169056

Ejemplares similares

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
por: Westerman, Mary E., et al.
Publicado: (2020)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
por: Kalathil, Suresh Gopi, et al.
Publicado: (2020)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
por: Mager, Layna, et al.
Publicado: (2023)

Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer
por: Ramshankar, Vijayalakshmi, et al.
Publicado: (2014)

Screening for hepatocellular carcinoma: patient selection and perspectives
por: Fateen, Waleed, et al.
Publicado: (2017)

Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2023)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives
por: Zimmerman, Asha, et al.
Publicado: (2017)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
por: Bins, S, et al.
Publicado: (2017)

The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective
por: Kim, In-Ho, et al.
Publicado: (2022)

Renal Cell Carcinoma with IVC Thrombi; Current Concepts and Future Perspectives
por: Nouh, Mohammed Ahmed Abdel-Muneem, et al.
Publicado: (2008)

Circular RNAs and their role in renal cell carcinoma: a current perspective
por: Liu, Zhongyuan, et al.
Publicado: (2021)

Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective
por: Huang, Chunjie, et al.
Publicado: (2023)

Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives
por: Ochoa, Cesar E., et al.
Publicado: (2018)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3p8tmuhonng17s607ug5bpuvs0